Cutera, Inc. (NASDAQ:CUTR) Director David B. Apfelberg sold 1,000 shares of the company’s stock in a transaction dated Wednesday, October 18th. The stock was sold at an average price of $39.90, for a total value of $39,900.00. Following the completion of the sale, the director now owns 10,259 shares in the company, valued at approximately $409,334.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
David B. Apfelberg also recently made the following trade(s):
- On Monday, September 18th, David B. Apfelberg sold 1,000 shares of Cutera stock. The shares were sold at an average price of $38.45, for a total value of $38,450.00.
Cutera, Inc. (NASDAQ:CUTR) traded up 2.23% during mid-day trading on Friday, hitting $39.00. The stock had a trading volume of 98,457 shares. Cutera, Inc. has a one year low of $12.45 and a one year high of $44.40. The stock has a market cap of $546.20 million, a P/E ratio of 83.87 and a beta of 0.53. The company has a 50 day moving average price of $40.43 and a 200 day moving average price of $29.64.
Cutera (NASDAQ:CUTR) last posted its quarterly earnings results on Monday, August 7th. The medical device company reported $0.13 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.03 by $0.10. The business had revenue of $36.40 million during the quarter, compared to the consensus estimate of $32.08 million. Cutera had a net margin of 5.07% and a return on equity of 11.64%. Cutera’s revenue for the quarter was up 32.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.07 earnings per share. On average, equities analysts anticipate that Cutera, Inc. will post $0.52 EPS for the current year.
Cutera declared that its board has authorized a stock buyback plan on Monday, August 7th that authorizes the company to repurchase $25.00 million in shares. This repurchase authorization authorizes the medical device company to buy up to 6.8% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.
WARNING: “Cutera, Inc. (CUTR) Director Sells $39,900.00 in Stock” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.dispatchtribunal.com/2017/10/28/cutera-inc-cutr-director-sells-39900-00-in-stock.html.
A number of brokerages have commented on CUTR. BidaskClub raised Cutera from a “hold” rating to a “buy” rating in a report on Saturday, August 12th. Roth Capital increased their price target on Cutera from $32.00 to $39.00 and gave the company a “buy” rating in a report on Tuesday, August 8th. TheStreet raised Cutera from a “c” rating to a “b” rating in a research note on Friday, August 18th. Gabelli reissued a “buy” rating on shares of Cutera in a research note on Wednesday, August 9th. Finally, Maxim Group cut Cutera from a “buy” rating to a “hold” rating in a research note on Thursday, September 14th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $37.33.
Institutional investors have recently added to or reduced their stakes in the company. American International Group Inc. boosted its holdings in shares of Cutera by 7.0% in the first quarter. American International Group Inc. now owns 7,221 shares of the medical device company’s stock valued at $149,000 after buying an additional 475 shares during the period. Nationwide Fund Advisors boosted its holdings in shares of Cutera by 8.4% in the second quarter. Nationwide Fund Advisors now owns 7,216 shares of the medical device company’s stock valued at $187,000 after buying an additional 561 shares during the period. Metropolitan Life Insurance Co. NY acquired a new position in shares of Cutera in the first quarter valued at approximately $202,000. Cubist Systematic Strategies LLC acquired a new position in shares of Cutera in the second quarter valued at approximately $225,000. Finally, PNC Financial Services Group Inc. acquired a new position in shares of Cutera in the second quarter valued at approximately $241,000. Institutional investors own 89.78% of the company’s stock.
Cutera Company Profile
Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.
Receive News & Ratings for Cutera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera Inc. and related companies with MarketBeat.com's FREE daily email newsletter.